Japan Osteoarthritis Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (NSAIDs, Corticosteroids, Analgesics, and Others), By Route of Administration (Parenteral Route, Topical Route, and Oral Route), By End-use (Hospital Pharmacies, Retail Pharmacies, and Others), and Japan Osteoarthritis Therapeutics Market Insights, Industry Trend, Forecasts to 2035

Japan Osteoarthritis Therapeutics Market Insights Forecasts to 2035

• The Japan Osteoarthritis Therapeutics Market Size Was Estimated at USD 535.2 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 8.16% from 2025 to 2035
• The Japan Osteoarthritis Therapeutics Market Size is Expected to Reach USD 1268.5 Million by 2035

According to a research report published by Spherical Insights & Consulting, The Japan Osteoarthritis Therapeutics Market Size is anticipated to reach USD 1268.5 Million by 2035, Growing at a CAGR of 8.16% from 2025 to 2035. The osteoarthritis therapeutics market in Japan is driven by growing populations, rising biologic treatment demand, and regenerative therapy developments.  Additionally, the market is anticipated to develop during the forecast period due to the growing use of non-surgical treatments.

Market Overview

Osteoarthritis therapeutics refer to medical procedures, drugs, and treatments, which are marked with a degenerative joint condition, including pain, decreased cartilage, and joint pain, to control, delay or reduce signs and symptoms of osteoarthritis. By treating pain, swelling, and joint pain, osteoarthritis treatments aim to control the symptoms and progression of the disease. There are many different treatment options available, including drugs, physical therapy, and surgery, all of which are aimed at increasing mobility and improving the quality of life for people with this chronic disease. These treatments include non-pharmacological approaches such as physical therapy, lifestyle changes, and nutritional supplements, as well as NSAIDs, analgesics, corticosteroids, disease-modifying drugs, biology, and new regenerative remedies. Osteoarthritis is a common musculoskeletal condition that affects millions of people, especially the elderly. The main weight-bearing joints affected are the knees, hips, and spine, resulting in chronic pain, edema, and low mobility. Treatment for osteoarthritis aims to reduce symptoms, increase joint function, and slow down the course of the condition. Increasing joint lubrication and promoting tissue regeneration are goals of biological therapy, such as platelet-rich plasma (PRP) treatment and hyaluronic acid injections. Stem cell therapy and tissue engineering are two examples of regenerative medical progress that are being investigated to repair damaged cartilage and perhaps prevent the progression of the disease.

Report Coverage

This research report categorizes the market for the Japan osteoarthritis therapeutics market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan osteoarthritis therapeutics market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan osteoarthritis therapeutics market.

Driving Factors

The osteoarthritis therapeutics market in Japan is driven by increased use of innovative treatments, better diagnostic capabilities, and more disease awareness.  Furthermore, there is promise for better results in the management of osteoarthritis through further research and development in regenerative medicine, targeted medication delivery, and customized therapy approaches.

Restraining Factors

The osteoarthritis therapeutics market in Japan is mostly constrained by high treatment costs, a lack of sophisticated regenerative technologies, strict regulatory approvals, possible pharmacological side effects, a sluggish uptake of new biologics, and doubts about the long-term effectiveness of disease-modifying therapies.

Market Segmentation

The Japan osteoarthritis therapeutics market share is classified into drug class, route of administration, and end-use.

• The analgesic segment accounted for a significant share in 2024 and is expected to grow at a remarkable CAGR during the forecast period.

The Japan osteoarthritis therapeutics market is segmented by drug class into NSAIDs, corticosteroids, analgesics, and others. Among these, the analgesic segment accounted for a significant share in 2024 and is expected to grow at a remarkable CAGR during the forecast period. This is due to its combined cycle plants, which may produce a lot more energy from the same quantity of fuel by using both gas and steam turbines. Furthermore, this technology is an environmentally responsible choice because it cuts emissions in addition to fuel usage.

• The parenteral route segment dominated in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Japan osteoarthritis therapeutics market is segmented by route of administration into parenteral route, topical route, and oral route. Among these, the parenteral route segment dominated in 2024 and is expected to grow at a significant CAGR during the forecast period. This dominance due to its greater anticipated growth rate, improved pharmacokinetics and pharmacodynamics, convenience of administration, and effectiveness for specific treatments.  Furthermore, the mounting evidence of placental tissue matrix injections is anticipated to fuel their increased use in the treatment of osteoarthritis.

• The hospital pharmacies segment dominated in 2024 and is expected to grow at a substantial CAGR during the forecast period.

The Japan osteoarthritis therapeutics market is segmented by end-use into hospital pharmacies, retail pharmacies, and others. Among these, the hospital pharmacies segment dominated in 2024 and is expected to grow at a substantial CAGR during the forecast period. This dominance is due to essential function in efficiently overseeing and controlling the treatment of osteoarthritis. Additionally, hospital pharmacies can quickly provide injections thanks to direct patient access, which is very helpful for patients who require acute symptom relief.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan osteoarthritis therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Seikagaku Corporation
• Ono Pharmaceutical Co., Ltd
• Shionogi & Co., Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan osteoarthritis therapeutics market based on the below-mentioned segments:

Japan Osteoarthritis Therapeutics Market, By Drug Class

• NSAIDs
• Corticosteroids
• Analgesics
• Others

Japan Osteoarthritis Therapeutics Market, By Route of Administration

• Parenteral Route
• Topical Route
• Oral Route

Japan Osteoarthritis Therapeutics Market, By End-Use

• Hospital Pharmacies
• Retail Pharmacies
• Others